The SENSible Blog discusses the development of rejuvenation biotechnology around the world: progress being made in the field of longevity, the design of medical therapies to cure, reverse and prevent the diseases and disabilities of aging, and much more.

Our content is a blend of popular interest articles – labelled “Easy Reads”, and designed to require no specific background knowledge – as well as more detailed scientific commentaries, labelled as “In-Depth” and aimed towards readers with some grounding in the biological/medical sciences.

In-Depth

More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

Read More »

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

Read More »

The Grand Opening of Our New Facilities

June 23, 2023 – SRF had the Grand Opening of our expanded Research Center in Mountain View, CA. In attendance were local and state dignitaries, members of the SRF Board, SRF senior staff and scientific leads, SRF staff and Education program participants, and a number of distinguished and welcome guests.

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can